BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 33227394)

  • 1. CUL4B promotes aggressive phenotypes of renal cell carcinoma via upregulating c-Met expression.
    Chen S; Wang Y; Chen L; Xia Y; Cui J; Wang W; Jiang X; Wang J; Zhu Y; Sun S; Zou Y; Gong Y; Shi B
    Int J Biochem Cell Biol; 2021 Jan; 130():105887. PubMed ID: 33227394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
    Gibney GT; Aziz SA; Camp RL; Conrad P; Schwartz BE; Chen CR; Kelly WK; Kluger HM
    Ann Oncol; 2013 Feb; 24(2):343-349. PubMed ID: 23022995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of Cullin1 is increased in renal cell carcinoma and promotes cancer cell proliferation, migration, and invasion.
    Ping JG; Wang F; Pu JX; Hou PF; Chen YS; Bai J; Zheng JN
    Tumour Biol; 2016 Sep; 37(9):12823-12831. PubMed ID: 27449035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
    Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
    Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cullin 4B regulates cell survival and apoptosis in clear cell renal cell carcinoma as a target of microRNA-217.
    Yang HF; Wang ZL; Mao TT; Liu JC
    Kaohsiung J Med Sci; 2021 Feb; 37(2):121-127. PubMed ID: 33022894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CUL4B promotes metastasis and proliferation in pancreatic cancer cells by inducing epithelial-mesenchymal transition via the Wnt/β-catenin signaling pathway.
    He YM; Xiao YS; Wei L; Zhang JQ; Peng CH
    J Cell Biochem; 2018 Jul; 119(7):5308-5323. PubMed ID: 29274277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2.
    Qi M; Jiao M; Li X; Hu J; Wang L; Zou Y; Zhao M; Zhang R; Liu H; Mi J; Zhang L; Liu L; Gong Y; Han B
    Oncogene; 2018 Feb; 37(8):1075-1085. PubMed ID: 29106389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UBE2T promotes proliferation and regulates PI3K/Akt signaling in renal cell carcinoma.
    Hao P; Kang B; Li Y; Hao W; Ma F
    Mol Med Rep; 2019 Aug; 20(2):1212-1220. PubMed ID: 31173226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adrenomedullin blockade suppresses sunitinib-resistant renal cell carcinoma growth by targeting the ERK/MAPK pathway.
    Gao Y; Li J; Qiao N; Meng Q; Zhang M; Wang X; Jia J; Yang S; Qu C; Li W; Wang D
    Oncotarget; 2016 Sep; 7(39):63374-63387. PubMed ID: 27556517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CUL4B Promotes Breast Carcinogenesis by Coordinating with Transcriptional Repressor Complexes in Response to Hypoxia Signaling Pathway.
    Huang W; Zhang J; Huo M; Gao J; Yang T; Yin X; Wang P; Leng S; Feng D; Chen Y; Yang Y; Wang Y
    Adv Sci (Weinh); 2021 May; 8(10):2001515. PubMed ID: 34026424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
    Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
    J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations.
    Bellon SF; Kaplan-Lefko P; Yang Y; Zhang Y; Moriguchi J; Rex K; Johnson CW; Rose PE; Long AM; O'Connor AB; Gu Y; Coxon A; Kim TS; Tasker A; Burgess TL; Dussault I
    J Biol Chem; 2008 Feb; 283(5):2675-83. PubMed ID: 18055465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circular RNA hsa_circ_0054537 sponges miR-130a-3p to promote the progression of renal cell carcinoma through regulating cMet pathway.
    Li R; Luo S; Zhang D
    Gene; 2020 Sep; 754():144811. PubMed ID: 32464246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
    Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
    Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of the miR-194-CUL4B negative feedback loop drives tumorigenesis in non-small-cell lung carcinoma.
    Mi J; Zou Y; Lin X; Lu J; Liu X; Zhao H; Ye X; Hu H; Jiang B; Han B; Shao C; Gong Y
    Mol Oncol; 2017 Mar; 11(3):305-319. PubMed ID: 28164432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-κB signaling axis.
    Wang Y; Su J; Wang Y; Fu D; Ideozu JE; Geng H; Cui Q; Wang C; Chen R; Yu Y; Niu Y; Yue D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):386. PubMed ID: 31481087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN.
    Deng W; Han W; Fan T; Wang X; Cheng Z; Wan B; Chen J
    Biomed Pharmacother; 2018 Nov; 107():1505-1513. PubMed ID: 30257368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CUL4B/miR-33b/C-MYC axis promotes prostate cancer progression.
    Zhao M; Qi M; Li X; Hu J; Zhang J; Jiao M; Bai X; Peng X; Han B
    Prostate; 2019 Apr; 79(5):480-488. PubMed ID: 30609075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CUL4B enhances the malignant phenotype of esophageal squamous cell carcinoma by suppressing TGFBR3 expression.
    Gong Q; Wang Y; Zhu K; Bai X; Feng T; Sun G; Wang M; Pan X; Qin C
    Biochem Biophys Res Commun; 2023 Oct; 676():58-65. PubMed ID: 37487438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CUL4B promotes aggressive phenotypes of HNSCC via the activation of the Wnt/β-catenin signaling pathway.
    Wang Y; Yue D
    Cancer Med; 2019 May; 8(5):2278-2287. PubMed ID: 30883036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.